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There are an estimated 38 million people living with HIV, with significant economic 
consequences. We aimed to collate global lifetime costs for managing HIV.  
Design:  
We conducted a systematic review (PROSPERO:CRD42020184490) using five databases 
from 1999-2019.  
Methods: 
Studies were included if they reported primary data on lifetime costs for people living with 
HIV. Two reviewers independently assessed the titles and abstracts, and data were extracted 
from full texts: lifetime cost, year of currency, country of currency, discount rate, time 
horizon, perspective, method used to estimate cost, and cost items included. Descriptive 
statistics were used to summarize the discounted lifetime costs (2019 USD). 
Results: 
Of 505 studies found, 260 full-texts were examined and 75 included. Fifty (67%) studies 
were from high-income, 22 (29%) from middle-income and 3 (4%) from low-income 
countries. Of 65 studies which reported study perspective, 45 (69%) were healthcare provider 
and the remainder were societal. The median lifetime costs for managing HIV differed 
according to: 1) country income level: $5,221 (IQR:2,978–11,177) for low-income to 
$377,820 (IQR:260,176–541,430) for high-income; 2) study perspective: $189,230 
(IQR:14,794–424,069) for healthcare provider, to $508,804 (IQR:174,781–812,418) for 
societal; and 3) decision model: $190,255 (IQR:13,588–429,772) for Markov cohort, to 
$283,905 (IQR:10,558–453,779) for microsimulation models.  
Conclusions: 
Estimating the lifetime costs of managing HIV is useful for budgetary planning and to ensure 
HIV management is affordable for all. Furthermore, HIV prevention strategies need to be 
strengthened to avert these high costs of managing HIV. 
 







People living with HIV have seen dramatic improvements in life expectancy and reductions 
in morbidity since HIV first came to medical attention in the early 1980s.[1-3] Antiretroviral 
therapy(ART) has revolutionized the management of people living with HIV. AIDS has 
shifted from what once was a fatal disease to now being a highly treatable chronic condition, 
becoming a condition people die with, rather than die from.[4, 5] 
 
ART initiation using CD4 cell count criteria has evolved since the late 1990s, at a time when 
drugs were expensive, less robust, with considerable side effects, and where the risk of 
resistance was high.[6] However, with ART becoming more affordable and less toxic, the 
decision to commence treatment regardless of CD4 cell counts is supported worldwide.[6] 
This is reflected in the WHO guidelines over time, in which the recommended CD4 cell 
count for initiation of ART rose from <200 cells/mm3 in 2002, to <350 cells/mm3 in 2010, to 
<500 cells/mm3 in 2013.[7] The latest WHO guidelines in 2015 recommend commencing 
ART in all people living with HIV regardless of CD4 cell count, as evidence shows the 
clinical and preventative benefits of starting ART early at high CD4 cell counts now 
outweigh their minimal risks.[6, 7] 
 
These advances in HIV management impact the lifetime costs associated with HIV as 
patients are starting ART earlier and living longer.[3, 8] Estimating an accurate lifetime cost of 
managing HIV is vital for policy makers who are involved in future planning and decision 
making to ensure quality HIV treatment is cost effective and affordable for all.[8] Thus, it is 
important that lifetime costs are calculated accurately and consistently to draw true 
conclusions regarding the economic burden of HIV, and to be able to compare lifetime costs 
of HIV around the world. 
 
To our knowledge, there have been no reviews that synthesized the global estimates of 
lifetime cost of managing HIV over time. In this review, we aimed to examine the published 
literature from 1999 onwards to compare the lifetime costs for a patient living with HIV in 







Search strategy and selection criteria 
We searched databases PubMed, EconLit, Web of Science: Core Collection, Embase via 
Ovid and Global Health Cost Consortium[9] on 23rd January 2020. The MeSH search terms 
used were related to ‘HIV’, ‘cost*’, ‘econ*’ and ‘lifetime’. When searching on the Global 
Health Cost Consortium database, we limited our review to ‘HIV’, ‘Treatment and Care’, and 
‘Adult ART’. We also restricted the language of studies to English. Our search strategy is 
shown in Appendix 1. The inclusion criteria were, any study published from 1999 onwards, 
and contained information about lifetime costs related to HIV. We excluded studies related to 
the costs of paediatric HIV management as these are quite different from adult HIV 
management costs and will be a subject of future research. Titles and abstracts were 
independently assessed for eligibility by at least two reviewers (TH, ML, KS). Another 
reviewer (JO) resolved any discrepancies. This systematic review has been registered at the 
International Prospective Register of Systematic Reviews (PROSPERO: CRD42020184490). 
 
Data analysis 
An extraction file was created in Microsoft Excel, to collate the following information: 
lifetime cost of HIV, age at which lifetime cost estimate begins, year of currency, country of 
currency, country, discount rate, time horizon, sensitivity analyses performed, perspective, 
methods used to estimate cost, model used to estimate lifetime cost, and cost items included. 
Data extraction was conducted by three reviewers (TH, ML, KS), and a fourth reviewer (JO) 
resolved any discrepancies. The quality of the study was assessed using the criteria from the 
methods section of the Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) checklist[10], with an average score of 7.5 (range 5-10) (Supplementary Table 3). 
 
To ensure consistency of comparison for the lifetime cost, we converted all currencies to US 
dollars (USD) using OFX Historical Exchange Rates.[11] We then inflated costs to 2019 using 
the relevant consumer price indices.[12] For studies that reported multiple estimates of lifetime 
costs, we used the average of the lowest and highest estimates in our model. For studies 
which had two price years for their lifetime cost, e.g. 2018/19, we used the latest year for the 
conversion and inflation. We classified the study country income level into high, upper 
middle, lower middle or low income using The World Bank classification.[13] We categorized 
the studies into healthcare provider (only costs incurred by the health provider), societal 




modified societal perspective (which may exclude some individual costs) based on what the 
study reported. If no perspective was reported, the study was categorized into an unknown 
perspective. We also categorised the decision models as cohort (based on populations), 
microsimulation (based on individuals) or other. 
 
Descriptive statistics were used to summarize the lifetime costs, including box plots to 
visualize the impact of the country income level, study perspective, decision model on the 
resultant lifetime cost of HIV. Costs were converted to a log scale in the box plots. We used 
the Kruskal Wallis test to determine if there was a statistically significant difference between 
the groups described above. We also examined for significant changes in price over time 
using a linear regression model. We defined a p value of <0.05 as statistically significant. All 
statistical analysis was performed using STATA version 16 (StataCorp. 2019. Stata 
Statistical Software: Release 16. College Station, TX: StataCorp LLC). This review is 
reported as per PRISMA guidelines. 
 
RESULTS 
Seventy-five studies were included in the analysis, where information on estimated lifetime 
costs and economic models used in informing these estimates were extracted (Fig. 1). 
 
Lifetime costs according to country-income level (Figure 2) 
Of 75 studies, 50 (66.7%) were from high-income countries, 15 (20.0%) from upper middle-
income countries, seven (9.3%) from lower middle-income countries, and three (4.0%) from 
low-income countries. There were statistically significant differences (p<0.0001) between the 
median lifetime cost for managing HIV in a high-income country was $377,820; 
IQR:260,176 - 541,430), upper middle-income country ($10,558; IQR:8,011 - 16,944), and 
low middle-income country ($3,693; IQR: 3,344.50 - 10,859). There were only three studies 
from low-income countries; all were from sub-Saharan Africa ($2978,[14] $11,177[15] and 
$5221[16]). There were statistically significant differences between the cost in high-income 
countries compared with all other country income levels (p<0.0001); but not between upper 
middle-income countries compared with lower middle-income countries (p=0.053) and low-
income countries (p=0.214); nor with lower-middle income compared with low-income 
countries (p=0.73). The wide variations of lifetime costs may be explained by the differences 




of a patient’s lifetime cost[3]. Even within the same income-country level, we can see that 
ART can differ greatly. For example, in the high-income country level, ART can range from 
53.6%[17] – 81.3%[18] of a lifetime cost. We did not find any statistically significant increase 
in costs over the years for high-income countries ($1,836/year, p=0.77), middle-income 
countries ($3,489/year, p=0.091) or low-income countries ($2,359/year, p=0.171). 
 
Lifetime costs according to study perspective (Figure 3) 
Supplementary Table 1 summarizes the lifetime costs, study perspective, income-country 
category and costs items for the included studies. Of 65 studies which explicitly stated their 
study perspective, 45 (69.2%) took a healthcare provider perspective, eight (12.3%) took a 
modified societal perspective, and 12 (18.5%) took a societal perspective. The median 
lifetime cost was $189,230 (IQR:14,794 - 424,069) for studies using a health provider 
perspective, $12,694 (IQR 8,217-196,746) for modified societal, $508,804 (IQR:174,781-
812,418) for societal and $318,644 (IQR:5,221-453,779) for unknown perspective. There 
were a statistically significant difference between studies adoping a healthcare provider 
perspective compared with societal (p=0.036) but not modified societal (p=0.056). There was 
also a difference between modified societal compared with societal (p=0.017). When we 
examined the cost items included within each study perspective, we found that they varied 
significantly (Supplementary Table 1). For example, we expect those who use a societal 
perspective to include productivity loss but only 50% (6/12) of these studies explicitly 
mentioned collecting costs related to productivity loss. It is also noteworthy that many studies 
did not completely report all cost items included in their analysis.  
 
Decision models used to estimate lifetime costs (Figure 4) 
Supplementary Table 2 presents a summary of methodologies of the included studies by costing 
and modelling approaches, decision model types, sensitivity analyses and whether CD4 status 
was accounted for. Of 75 studies, 64 (85%) used Markov models; among these 64 studies, 32 
(50%) state-transition cohort models, 31 (48%) microsimulation models, and 1 (1.6%) dynamic 
Markov model. Of 31 microsimulation models, 18 used the Cost-Effectiveness of Preventing 
AIDS Complications (CEPAC) model, and four the Anti-Retroviral Analysis by Monte Carlo 
Individual Simulation (ARAMIS) model. Of the remaining 11 studies, two were discrete event 
simulation (DES) models, one an econometric model, one a decision tree, four mathematical 




The median lifetime costs for people living with HIV differed according to the decision model: 
$283,905 (IQR:10,558-453,779) for microsimulation models, $190,225 (IQR:13,588-429,772) 
for Markov cohort, and $321,340 (IQR: 102,336 – 761,714) for other model types. There were 
no statistically significant differences between studies using Markov cohort compared with 
microsimulation models (p=0.773) or other (p=0.510); and microsimulation models compared 
with other (p=0.244). Table 1 further disaggregates the lifetime costs according to the country 
income level and model used. The choice to use cohort or microsimulation models did not 
significantly change lifetime costs across all country income levels.  
Future comorbidity associated with HIV 
Whilst many studies acknowledged that HIV-related chronic comorbidities may arise, very 
few studies actually accounted for comorbidity associated with HIV, particularly those 
associated with an ageing population. From a health system planning perspective, it is not 
only the direct costs of the disease that are considered, but also the costs of comorbidities and 
even unrelated future medical costs that may be incurred by not dying from HIV, and living 
longer. Several studies considered the link between HIV and cardiovascular disease within 
their lifetime cost[19-21] however, each performed different calculations. One incorporated the 
costs of a 1.5- to 2-fold increased relative risk of cardiovascular disease compared with the 
general population in their model.[19] Another used the Framingham equation to predict 
coronary heart disease and stroke, and accounted for this within ‘care of chronic disease’ 
costs.[20] Finally, one calculated a monthly weighted mean cost of acute myocardial infarction 
(40%) and hypokinetic cardiomyopathy (60%) based on ‘expert opinion’.[21] Another 
approach included the cost of medications for comorbidity[22] where 15% of the total lifetime 
costs were related to chronic disease medications, opportunistic infection prophylaxis, and 
treatment medications.  
 
Lifetime costs according to patient subpopulation 
Only three of 75 studies reported lifetime costs by subpopulation. This approach was taken 
by Brogan et al.,[23] who identified key cost differences between heterosexuals, men who 
have sex with men (MSM), and people who inject drugs (PWID).[23] The lifetime costs (USD 
2019) were $461,952, $575,972, and $635,663, respectively, with the most costly group 
being people who inject drugs. Ong et al,[24] identified cost differences between 
heterosexuals, MSM and PWID, but found different results to Brogan et al.[23] The lifetime 




the most costly group being MSM. Populations vulnerable to HIV acquisition can also be 
stratified by skin colour, ethnicity, and gender. Ethnic minority populations are more likely to 
have delayed diagnosis, and are less likely to engage with treatment services.[25, 26] 
Schackman et al,[22] provides estimates from 15 subpopulations: MSM, male and female 
PWID, male and female heterosexuals, and ethnic groups of White, Black or Hispanic.[22] By 
disaggregating the data, Schackman highlighted the discrepancies in lifetime costs between 
subpopulations, with the greatest difference seen in Hispanic MSM with a lifetime cost 
($394,395) greater than double that of Black female PWID ($193,412).[22] 
 
DISCUSSION 
This systematic review reported lifetime costs from 75 studies across the world for managing 
HIV according to country income level, study perspective, and decision model; using studies 
published between 1999 and 2019. Though there is a need for locally derived lifetime cost 
estimates, our data could be used as approximations of possible ranges of costs to assist 
governments with budgetary planning when no local estimates exist. Given significant 
variations noted in the literature, we recommend a standardised methodology for measuring 
lifetime HIV costs to improve comparability in future studies. We noted key knowledge gaps 
within the literature on costs disaggregated by subpopulation and the inclusion of 
comorbidity associated with an ageing population of people living with HIV.  
 
In a infection such as HIV, which disproportionately affects certain subpopulations, it is 
important to consider the heterogeneity of economic impacts which result within these 
subpopulations. By performing subgroup analyses on populations defined by transmission 
risk, gender, and ethnicity, it highlights the large variation of lifetime costs in these key 
populations. Minority groups often experience structural and social barriers to timely access 
to medical care and ART.[25] And so, these vulnerable populations are more likely to be 
diagnosed at a more advanced disease stage, which is associated with higher healthcare 
utilisation and thus, higher lifetime costs.[26] Combined with the cost of an extended lifespan, 
managing HIV could be more expensive for high-risk individuals.[26] These racial and ethnic 
differences not only affect disease morbidity and mortality, but also health service 
utilisation.[25] It is important to capture these differences through subgroup analyses. We 




study population. These subgroup analyses enable decision-makers to identify the groups for 
which treatment is costly, and helps prioritize prevention efforts and reduce health inequities. 
Although there may be differences in cost according to subpopulation, we must also account 
for the benefit of downstream transmissions averted by a person having an undetectable viral 
load within that subpopulation.  
 
There is increasing discussion that medical advancements that can prolong life should be 
considered when estimating the lifetime cost of a disease.[27] With HIV now regarded as a 
chronic disease, there are additional HIV-related comorbidity that come with ageing that 
might significantly affect the lifetime cost calculations for people living with HIV. Most 
studies we reviewed did not include this in their estimation. Further, it may be important to 
consider a broad societal perspective when estimating the lifetime cost of a chronic infection 
such as HIV. For a person living with HIV, there could be significant indirect costs--
opportunity and productivity costs--that may have a large impact on both the individual and 
society.[25] With the inclusion of the cost of managing HIV-related comorbidity—particularly 
with an ageing population of people living with HIV, a more accurate and realistic estimation 
of lifetime cost of HIV will result.[5] This will have important implications not only for 
individuals but also for the healthcare systems, in relation to resource utilization, allocation 
and cost expenditure.[26] 
 
Even though the majority of studies adopted a healthcare provider perspective, we found that 
the cost items included were inconsistently measured. This matters for health system 
planning and for comparability of total costs between different settings. There was also an 
issue with transparency as it was often unclear as to which cost items were included, and how 
they were calculated. Thus, we recommend that a standardised checklist of cost items from a 
broad societal perspective be adopted for future studies, with clear disclosure on cost items 
included and how they were derived. HIV costing guidelines has already been developed by 
UNAIDS[28], and the Global Health Cost Consortium provides guidance for estimating the 
unit costs of a health intervention,[29] but there is no consensus on how to estimate the 
lifetime costs for managing HIV. Having a standardized methodology would ensure 






Since HIV is a complex disease which requires lifelong management, it is important to use a 
decision model that captures the key relevant events in a patients’ lifetime. The dominant 
decision model used was a Markov cohort model (32 of 75 studies) that classified health 
states based on CD4 count status which seems appropriate, as long as readers are aware of the 
assumption of the memoryless property of Markov models.[30] The second most predominant 
type of model (31 of 75 studies) was the microsimulation models (most commonly the 
CEPAC model) which can account for the history of a simulated individual. Although 
choosing a Markov cohort model or microsimulation approach have different strengths and 
limitations,[31] interestingly, we did not find significant differences in the estimation of 
lifetime costs according to the decision model used; but estimates using microsimulation 
models had less variation compared with cohort models. We found one study which used a 
decision tree model.[32] Over the course of a lifetime, a person experiences numerous clinical 
conditions that may recur, as well as be uncertain in nature; so a decision tree might not be 
the right tool for interventions to treat for such conditions because of the complexity and 
inconvenience of representing all probable sequences of events over the entire course of a 
person’s lifetime (or alternative time horizon).  
 
To our knowledge, this is the first attempt to provide an overview of the large number of 
studies reporting lifetime cost for people living with HIV. This allowed us to understand the 
strengths and limitations in the literature and to provide direction for future studies, for 
example, the need for disaggregated data by subpopulation. Our study should be read in light 
of some limitations. First, there is the potential for publication bias as we could not access 
any unpublished data from pharmaceutical companies which were submitted to funding 
bodies that could contain economic models estimating lifetime costs. It is unclear the impact 
this would have on our findings. Second, there was large heterogeneity in the methods used 
for estimating lifetime costs, precluding the use of meta-analysis methods. Thus, we present 
the data using descriptive statistics instead. Third, the models included in our review do not 
take into account the treatment costs of secondary transmission averted by treating the index 
case – they only examine the lifetime cost of managing HIV in the index case. Therefore, 
although the cost of managing HIV may be relatively expensive compared to non-
communicable diseases, there is an added benefit of averting secondary transmissions when 
an index patient has undetectable HIV viral load; this is not presently captured within the 
metric of lifetime HIV costs. This additional benefit should be accounted for in economic 






We found variations in the estimation of lifetime costs of managing HIV, which could be 
accounted for partly by country-income level, study perspective, and variations in cost-items 
included. Although decision models have different strengths and limitations, lifetime costs 
were not sensitive to the decision model used. There was a paucity of studies that 
disaggregated lifetime costs by subpopulation and inconsistencies in the inclusion of 
comorbidity for the aging HIV population. There is a need for a standardised methodology to 
allow comparability of lifetime costs of HIV globally. We recommend future studies 
disaggregate data by subpopulation and suggest the inclusion of non-HIV-related costs 
associated with ageing and comorbidity (at least as a sensitivity analysis), to determine a 
more accurate cost of managing HIV. 
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Cohort 22 355,577 182,661-502,763 109,586 927,428 
Micro- 
simulation 
19 383,168 318,023-500,311 11,807 671,301 




Cohort 5 13,236 9,140-13,941 8,462 191,221 
Micro- 
simulation 
7 10,588 8,011-16,944 5,576 337,112 




Cohort 3 4,494  3,644 10,859 
Micro- 
simulation 
4 3,519  1,414 13,582 
Low- 
income 
Cohort 2   5,221 11,177 
Micro- 
simulation 


































Appendix 1. Search Strategy 
1.  PubMed 
Set Search Results 
#1 ((("hiv"[MeSH Terms] OR "hiv"[All Fields]) AND "cost*"[All Fields]) AND 
"econ*"[All Fields]) AND ("lifetime"[All Fields] OR "lifetimes"[All Fields]) 
335 
#2 #1 with Filters: from 1999 – 2019 277 
#3 #2 with Filters: Humans, from 1999 – 2019 260 
#4 #3 with Filters: Humans, English, from 1999 – 2019 259 
  
2.  EconLit 
Set Search Results 
#1 HIV AND cost* AND econ* AND lifetime with Filters: from 1999 – 2019 6 
  
3.  Web of Science: Core Collection 
Set Search Results 
#1 (HIV  AND cost*  AND econ*  AND lifetime) Timespan: 1999-2019 114 
  
4.  Embase via Ovid 
Set Search Results 
#1 (HIV and cost* and econ* and lifetime).mp. [mp=title, abstract, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword, floating subheading word, candidate term word] 
183 
#2 limit #2 to (human and english language and yr="1999 - 2019") 146 
  
5.  Global Health Cost Consortium [9] 
Set Search Results 
#1 Disease – HIV, Intervention Class – Treatment and Care, Intervention – Adult ART, Unit 






Supplementary Table 1. Lifetime cost estimates and cost items included.   




















































































































































Healthcare provider perspective 
Pinkerton et al, 1999[33] 899761 US (HIC) Y    Y Y     Y             
Johri et al, 2002[34] 148792 US (HIC) Y   Y Y Y Y Y   Y         
Liu et al, 2002[35] 141148 US (HIC)  Y    Y                   Y1 
Duggan et al, 2005[36] 175531 US (HIC) Y     Y Y                 
Hornberger et al, 2005[17] 177571 Italy (HIC) 
Y 
(54-
64%)   Y Y Y   Y             
Badri et al, 2006[37] 8011 
South Africa 
(UMIC) Y Y Y Y Y   Y     Y Y     
Cleary et al, 2006[38] 8462 
South Africa 
(UMIC) Y   Y Y  Y   Y   Y Y       
Simpson et al, 2008[39] 360391.5 US (HIC) Y   Y   Y   Y             
Simpson et al, 2009[40] 179728.5 US (HIC) Y  Y   Y Y    Y Y           
Kuhne et al, 2010[41] 371563.5 US (HIC) Y   Y  Y     Y Y Y         
Moreno et al, 2010[42] 419658.5 Spain (HIC) Y   Y    Y   Y   Y         
Broder et al, 2011[43] 323650.5 US (HIC) Y   Y    Y   Y Y           
Chawana et al, 2011[44] 13941 
South Africa 




Chaudhary et al, 2011[45] 
*methods taken from Tilden et 
al[46] 146769 
Australia 
(HIC)  Y   y      Y Y           
Lorenzana et al, 2012[47] 33711.5 
South Africa 
(UMIC) Y   Y Y Y                 










(5%) Y               
Sloan et al, 2012[49] 499082 France (HIC) 
Y 






(12%)  Y Y           
Bayoumi et al, 2013[50] 260175.5 
US, Canada, 
UK (HIC) Y Y         Y             
Farnham et al, 2013[51] 372472 US (HIC) Y Y Y Y Y Y Y Y           
Foglia et al, 2013[52] 300072 Italy (HIC) Y Y Y Y Y   Y Y           
Juday et al, 2013[53] 813031.5 US (HIC) Y   Y   Y   Y             
Leisegang et al, 2013[54] 13235.5 
South Africa 
(UMIC) Y   Y   Y                 





(1%)     
Y 
(11-




(4%)           
Walensky and Sax et al, 2013[55] 383168 US (HIC) Y   Y                    










(6%) Y               
Hyle et al, 2014[14] 2977.5 
Sub-Saharan 
Africa (LIC) Y   Y       Y             
Owiti et al, 2014[57] 4494 
Kenya 
(LMIC) Y                         
Ciaranello et al, 2015[58] 16944 
South Africa 
(UMIC) Y Y Y Y Y   Y Y           
Peng et al, 2015[59] 623667.5 US (HIC) 
Y 
(88%)   
Y 
(8-
9%)   Y    
Y 
(3%) Y            
Pialoux et al, 2015[60] 554572.5 France (HIC) 
Y 
(83%)   
Y 
(1-
2%)       
Y 
(1%)   
Y 
(1-
2%)         




(15%) Y Y Y Y               
Mann et al, 2016[32] 2211 
South Africa 




Sweet et al, 2016[61] 582460.5 US (HIC) Y Y Y Y Y Y Y             
Taychakhoonavudh et al, 
2016[62] 191221 
Thailand 
(UMIC)                           
Kowalska et al, 2017[63] 182661 
Poland 
(HIC) Y             Y  Y          
Moreno et al, 2017[20] 278080.5 Spain (HIC) Y   Y       Y Y           
Paltiel et al, 2017[64] 14794 
South Africa 
(UMIC) Y                         
Freedberg et al, 2018[65] 3693 
India 
(LMIC) Y   Y Y Y                 
Gray et al, 2018[66] 234392 
Australia 
(HIC) Y                         
Uthman et al, 2018[15] 11176.5 
Sub-Saharan 
Africa (LIC)       Y Y   Y             
Zheng et al, 2018[67] 3344.5 
India 
(LMIC) Y     Y Y                 
Brogan et al, 2019[23] 548807.5 UK (HIC) Y Y Y Y Y Y               
Dugdale et al, 2019[68] 10558 
South Africa 
(UMIC) Y                         
Ong et al, 2019[24] 189229.5 UK (HIC) Y     Y Y                 
Millham et al, 2020[69] 490462.5 US (HIC) Y                         
Modified societal perspective 
Freedberg et al, 2001[70] 109586 US (HIC) Y   Y     Y               
Yazdanpanah et al, 2002[71] 346057.5 France (HIC) Y   Y         Y Y         
Wolf et al, 2007[72] 11806.5 
Eastern 
Caribbean 




Bendavid et al, 2008[73] 5576 
South Africa 
(UMIC) Y   Y Y         Y         
Bender et al, 2010[74] 3643.5 
India 
(LMIC) Y   Y Y   Y               
Sax et al, 2010[75] 283905 US (HIC) Y     Y Y   Y   Y         




(LMIC) Y Y Y Y Y      Y Y    Y     
VanDeusen et al, 2015[77] 10859 
Ghana 
(LMIC) Y Y Y Y   Y  Y Y Y  Y Y Y   
Societal perspective 
Goldie et al, 2003[78] 350762 US (HIC) Y Y Y   Y   Y Y Y   Y     
Hutchinson et al, 2006[25] 1294344 US (HIC) Y Y Y Y Y Y Y           Y 
Schackman et al, 2007[79] 550459 US (HIC) Y                         
Bendavid et al, 2009[80] 9139.5 
South Africa 
(UMIC) Y   Y Y Y                 










(11%) Y Y   
Y 
(3%)       Y 




(10%)   Y Y Y     
Y 
(3%)         
Bendavid et al, 2011[83] 10242 
South Africa 
(UMIC) Y   Y  Y Y   Y             





9%) Y  Y Y Y 
Y 
(0.2-
0.3%)             
Ouellet et al, 2015[85] 968025 
Canada ( 
HIC) Y   Y Y Y Y       Y     Y 









85%)   Y Y Y   
Y (1-
2%) Y  
Y 




Adamson et al, 2019[88] 279777 US (HIC) Y Y Y   Y   Y   Y Y Y   Y 
Unknown perspective 
Mauskopf et al, 2005[89] 167329 US (HIC) Y   Y                     
Schackman et al, 2006[8] 500310.5 US (HIC) Y    Y Y Y   Y   Y         
Freedberg et al, 2007[90] 1414 
India 
(LMIC) Y Y Y Y Y   Y   Y         





(HIC) Y   Y Y Y   Y             
Sempa et al, 2012[16] 5221 
Uganda 
(LIC) Y Y Y Y     Y     Y       





71%)   Y                     
Nakagawa et al, 2015[3] 318,023 UK (HIC) 
Y 
(68%)   
Y 
(4%) Y Y   Y             
Restelli et al, 2017[21] 453779 Italy (HIC) Y   Y  Y   Y Y Y         
Rampaul et al, 2018[93] 319,264  (HIC)                           
Ward et al, 2018[94] 502763 UK (HIC) Y         Y             
The percentages represent the proportion of lifetime cost attributed to that cost item. These must be read with caution as the percentage will depend on what cost items are 
included in the study – i.e. the difference between studies may be due to methodological fabrication. 
1 This study reports using the employer’s perspective – cost items: direct expenses on health insurance premium, life insurance premium, short-term disability benefits, long-









Cost Methodology Model Microsimulation Cohort Sensitivity Analyses Accounted for 
CD4 
1. Adamson et al, 2019[88] Micro costing using 
ingredients-based approach 
at the clinic level. 
Health care costs were used 
from published data 
Markov 
(health states -memoryless) 
  
  
  🗹 One-way, Scenario, & Probabilistic Y 
2. Badri et al, 2006[37] Micro costing using step 
down accounting methods 
Monte Carlo simulated 
Markov state-transition 
model 
🗹   One-way & Probabilistic Y 
3. Bayoumi et al, 2013[50] 
  
Mixed costing 
Cost based on data from 
Dept of Veterans Affairs 
Markov cohort simulation 
model (monthly intervals) 
  🗹 one-way & Probabilistic Y 
4. Bendavid et al, 2011[83] Micro costing using 
published data 
State Transition Simulation 🗹   Several One-way, Multivariate & 
Probabilistic 
Y 









6. Bendavid et al, 2008[73] Micro costing using 
published data 
Markov Microsimulation 🗹   One-way, Multivariate Y 
7. Bender et al, 2010[74] Micro costing using 
published data 
State Transition Simulation    🗹 One-way, Multivariate Y 
8. Broder et al, 2011[43] Micro costing using 
published data 
Markov Microsimulation 🗹   One-way & Probabilistic Y 




  🗹 One-way, Multivariate & 
Probabilistic 
Y 
10. Brogan et al, 2014[56] Micro costing using 
published data 
Markov 
(3-month cycle period) 
  🗹 One-way & Probabilistic Y 
11. Brogan et al, 2011[84] Micro costing using 
published data 
Markov model 
(1-year cycle period) 
  🗹 One-way & Probabilistic Y 
12. Brogan et al, 2019[23] Micro costing using 
published data 
Markov model on 
Microsoft Excel 
(3-month health state 
transition) 
  🗹 One-way Y 
13. Chawana et al, 2011[44] Micro costing 
average inpatient & 
outpatient cost using 
published data 
Markov 
(1-year cycle period) 




14. Ciaranello et al, 2015[58] Micro costing using 
published data 
CEPAC - Monte Carlo 
State-Transition 
🗹   One-way, Multivariate Y 
15. Cleary et al, 2006[38] Mixed Transition State Markov   🗹 Multivariate & Probabilistic Y 
16. Dugdale et al, 2019[68] Micro costing using 
published data 
CEPAC - Monte Carlo 
State-Transition 
🗹   One-way, Multivariate Y 
17. Duggan et al, 2005[36] Claims and eligibility data 
from random 24% of 
Medicaid recipients from 
California 
Simple Time Series Model 
(econometric model) 
- - - Y 
18. Estill et al, 2015[92] Micro costing but source of 
data is unclear 
Mathematical Simulation 
Model 
- - One-way N 
19. Farnham et al, 2013[51] Micro costing 
Data extracted from hospital 
and clinic records. 
  
HIV-related costs derived 
from Gebo et al 
supplemented with data from 
Schackman et al 
PATH - Monte Carlo 
Health-State Transition 
Simulation 




20. Foglia et al, 2013[52] Micro costing 
Actual resource consumption 
recorded in Lombardy 
Region databank. 




🗹   Probabilistic Y 
21. Freedberg et al, 2018[65] Micro costing using 
published data 
CEPAC I- Monte Carlo 
State-Transition 
🗹   One-way, Multivariate Y 
22. Freedberg et al, 2001[70] Macro costing using data 
from the AIDS Cost and 
Services Utilization Survey, 
Payment Office at Boston 
Medical Center, Boston, and 
the 1998 Red Book 
(prophylaxis & annual cost 
of ART regimes) 
Computer Simulation 
Model of HIV, 
Monte Carlo Simulation 
  🗹 One-way Y 
23. Freedberg et al, 2007[90] Micro costing Resource 
utilisation from YRG CARE 
cohort 
+ Publications 
CEPAC I-Monte Carlo 
State-Transition 
🗹   One-way Y 
24. Goldie et al, 2003[78] Micro costing using 
published data 
Computer Simulation 
Model of HIV, 
Monte Carlo Simulation 




25. Gray et al, 2018[66] Micro costing using data 
from Australian HIV 
Observational Database 
(AHOD) 
Temporary Residents Access 
Study (ATRAS) 
Risk Equation Model -   One-way Y 
26. Hornberger et al, 2005[17] Macro Costing using Expert 
Panel, Published Studies, 
Cost Of Treating AIDS 
Defining Illness using DRGS 
Markov   🗹 One-way Y 




- - One-way Y 
28. Hyle et al, 2014[14] Micro costing using 
Published Data 
CEPAC I-Monte Carlo 
State-Transition 
🗹   One-way, Probabilistic Y 
29. Juday et al, 2013[53] Micro costing Product 





  🗹 One-way, Multivariate & 
Probabilistic 
Y 
30. Kuhne et al, 2010[41] Micro costing using 
published data 
ARAMIS Model - 
Microsimulation. Markov 
State Transition Diagram 




31. Lorenzana et al, 2012[47] Micro costing using South 
African Cohort and 
published data 
CEPAC I-Monte Carlo 
State-Transition 
(Monthly Transition) 
🗹   One-way, Multivariate Y 
32. Mauskopf et al, 2010[82] Micro costing using 
published and unpublished 
Studies using US database 
Markov Model- Monte 
Carlo Simulation 
🗹   One-way & Probabilistic Y 
33. Mann et al, 2016[32] Micro costing using Sentinel 
Active Surveillance Activity, 
combine with population 
data 
Decision tree model - - One-way & Probabilistic N 
34. Mauskopf et al, 2012[48] Micro costing using 
Resource Use Study 
& 
unit drug cost from Ontario 
Ministry of Health. 
  
Input cost based on hospital 
days from 48 weeks of 










35. Mauskopf et al, 2005[89] Micro costing using average 
wholesale prices from Drug 
Topics Red Book 2002 
Markov 
(6-month cycle) 
  🗹 One-way Y 
36. Millham et al, 2020[69] Micro costing using 
published data 
CEPAC - Monte Carlo 
State-Transition 
🗹   One-way, Multivariate & 
Probabilistic 
Y 
37. Nakagawa et al, 2015[3] Micro costing using 
published data 
HIV Synthesis Progression 
Model: individual-based 
stochastic computer 
simulation model (3 
monthly time step) 
🗹   One-way, Multivariate Y 
38. Moreno et al, 2017[20] Micro costing using 
published data 
Monte Carlo Individual 
Simulation (ARAMIS) 
🗹   One-way Y 
39. Ong et al, 2019[24] Micro costing using the 
British National Formulary 
list price for each ARV, non-
ARV costs from figures 
provided through Dept of 
Health 
Two cost estimation 
approaches (models) using 
the HIV and AIDS 
Reporting System (HARS) 
  🗹 One-way Y 
40. Ouellet et al, 2015[85] Micro costing using CHUM 
HIV cohort database 
Inventory of all costs 
consumed during the 
course of HIV 




41. Owiti et al, 2014[57] Micro costing using data 
from Mbagathi District 
Hospital (Mbagathi) and Moi 
Teaching and Referral 
Hospital (Moi) in Kenya. 
Markov   🗹 - Unclear 
42. Paltiel et al, 2017[64] Macro costing using 
published data 
CEPAC - Monte Carlo 
State-Transition 
🗹   One-way, Multivariate & 
Probabilistic 
Y 
43. Pinkerton et al, 1999[33] unclear 
Data from publications 
Unclear - 
a previously developed 
economic model of 
HIV/AIDS-related medical 
care costs 
- - - Y 
44. Reyes-Urueña et al, 2018[86] Micro costing 
Inventory of all health care 
inputs consumed during HIV 
disease was created 




45. Rampaul et al, 2018[93] Unclear how cost data 
collected - 
Used data from the South 
Carolina Department of 








(by John Snow Institute) 
& 
Draft Cost Analysis Model 
🗹   - Y 
46. Schackman et al, 2006[8] Estimated medical services 
utilisation data from cross-
sectional data 
collected by the HIV 
Research Network (HIVRN). 
& 
published data 
CEPAC - Monte Carlo 
State-Transition 
🗹   One-way Y 
47. Schackman et al, 2015[22] Mixed costing using data 
from HIV Research Network 









48. Sempa et al, 2012[16] Micro costing using 
published data 
Decision Analytic Model, 
Markov 
  🗹 One-way Y 
49. Sloan et al, 2012[49] Mixed costing using data 
from a clinical database 
CEPAC - Monte Carlo 
State-Transition 
🗹   One-way Y 
50. Yazdanpanah et al, 2002[71] Micro costing 
using a clinical database 
from Northern France 
Computer Based 
Simulation Model 
🗹   One-way, Multivariate Y 





🗹   One-way Y 
52. Uthman et al, 2018[15] Micro costing using 
published data 
Markov   🗹 One-way & Probabilistic Y 
53. VanDeusen et al, 2015[77] Micro costing using data 
from a retrospective review 
of 817 medical records at 
two 
hospitals in Ghana and 
published literature 
State-Transition Model   🗹 One-way Y 
54. Walensky and Ross 
et al, 2013[76] 
Micro costing using 
published data 
CEPAC - Monte Carlo 
State-Transition 
🗹   One-way Y 
55. Walensky et al, 2013[55] Micro costing using 
published data 
CEPAC - Monte Carlo 
State-Transition 
(US Model) 




56. Wolf et al, 2007[72] Model-based analysis 
incorporating 
data from different sites in 
the 
Caribbean, including OECS 
countries, Barbados, and 
Jamaica. 
CEPAC I- Monte Carlo 
State-Transition 
🗹   One-way Y 
57. Leisegang et al, 2013[54] Micro costing using 
electronic database and 
published data 
Markov   🗹 Multivariate & Probabilistic Y 
58 Liu et al, 2002[35] Micro costing using 
published data 
Cost Simulation Model - - One-way & Probabilistic Y 
59. Johri et al, 2002[34] Micro costing using 
published data 
CEPAC - Monte Carlo 
State-Transition 
🗹   One-way Y 
60. Kowalska et al, 2017[63] Micro costing using 
published data 
Markov   🗹 One-way, Multivariate & 
Probabilistic 
N 
61. Peng et al, 2015[59] Micro costing using 
published data 
Discrete-Event Simulation - - One-way & Probabilistic N 




🗹   One-way Y 
63. Restelli et al, 2017[21] Micro costing using 
published data 
ARAMIS-DTG model - 
Monte Carlo Individual 
Simulation Model 




64. Sax et al, 2010[75] Micro costing using 
published data 
CEPAC - Monte Carlo 
State-Transition 
🗹   One-way N 
65. Schackman et al, 2007[79] Unclear CEPAC - Monte Carlo 
State-Transition 
🗹   One-way N 
66. Simpson et al, 2013[18] Micro costing using 
published data 
Discrete Event Simulation 
(DES) 
- - One-way & Probabilistic Y 
67. Taychakhoonavudh et al, 
2016[62] 
Micro costing using the 
LASA study and published 
data 
Markov   🗹 One-way N 
68. Tilden et al, 2010[46]* 
*Lifetime cost was taken from 
Chaudhary et al, 2011[45] 
Unclear Markov   🗹 - N 
69. Tremblay et al, 2018[87] Micro costing using 
published data 
Dynamic Markov Model - - One-way & Probabilistic N 
70. Ward et al, 2018[94] Micro costing using 
published data 
Hybrid Decision Tree & 
Markov Model 
  🗹 - N 
71. Zheng et al, 2018[67] Micro costing using 
published data 
CEPAC I- Monte Carlo 
State-Transition 
🗹   Multivariate & Probabilistic N 
72. Moeremans et al, 2010[91] Micro costing using 
published data 
Markov   🗹 One-way & Probabilistic Y 
73. Moreno et al, 2010[42] Micro costing using 
published data 




74. Simpson et al, 2009[95] Micro costing using 
published data 
Markov   🗹 Multivariate Y 
75. Simpson et al, 2008[39] Micro costing using 
published data 







Supplementary Table 3. Quality of the study assessed using the criteria from the methods section of the Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS) checklist[10] 
# Study Methods  




























1. Adamson et al, 2019[88] 1 1 1 1 1 1 1 1 1 0 9 
2. Badri et al, 2006[37] 1 1 1 1 1 1 1 1 1 0 9 
3. Bayoumi et al, 2013[50] 1 1 1 0 1 1 0 1 1 1 8 
4. Bendavid et al, 2011[83] 1 1 1 1 1 1 1 1 1 0 9 
5. Bendavid et al, 2009[80] 1 1 1 1 1 1 1 1 0 0 8 
6. Bendavid et al, 2008[73] 1 1 1 1 1 1 1 0 1 0 8 
7. Bender et al, 2010[74] 1 1 1 1 1 1 1 1 1 0 9 
8. Broder et al, 2011[43] 1 1 1 1 1 1 1 1 1 0 9 
9. Brogan et al, 2010[81] 1 1 1 1 1 1 1 1 1 0 9 
10. Brogan et al, 2014[56] 1 1 1 1 1 1 1 1 1 1 10 
11. Brogan et al, 2011[84] 1 1 1 1 1 1 1 1 1 0 9 
12. Brogan et al, 2019[23] 1 1 1 1 1 1 1 1 0 1 9 
13. Chawana et al, 2011[44] 1 1 1 1 1 1 0 1 1 0 8 
14. Ciaranello et al, 2015[58] 1 1 1 1 1 1 1 1 0 0 8 
15. Cleary et al, 2006[38] 1 1 1 1 1 1 1 1 0 0 8 
16. Dugdale et al, 2019[68] 1 1 1 1 1 1 1 1 1 1 10 
17. Duggan et al, 2005[36] 1 1 1 1 0 1 0 1 1 0 7 
18. Estill et al, 2015[92] 1 1 1 1 1 1 1 1 0 0 8 
19. Farnham et al, 2013[51] 1 1 1 1 1 1 1 1 1 1 10 
20. Foglia et al, 2013[52] 1 1 1 1 1 1 0 1 0 0 7 
21. Freedberg et al, 2018[65] 1 1 1 1 1 1 1 1 1 0 9 
22. Freedberg et al, 2001[70] 1 1 1 1 1 1 1 1 1 0 9 
23. Freedberg et al, 2007[90] 1 1 1 1 1 1 1 1 1 0 9 
24. Goldie et al, 2003[78] 1 0 1 1 1 1 0 1 1 1 8 
25. Gray et al, 2018[66] 1 1 1 1 1 1 0 1 1 0 8 




27. Hutchinson et al, 2006[25] 1 1 1 1 1 1 1 0 1 1 9 
28. Hyle et al, 2014[14] 1 1 1 1 1 1 1 1 1 0 9 
29. Juday et al, 2013[53] 1 1 1 1 1 1 1 1 1 0 9 
30. Kuhne et al, 2010[41] 1 1 1 1 1 1 1 1 1 1 10 
31. Lorenzana et al, 2012[47] 1 1 1 1 1 1 1 1 1 1 10 
32. Mauskopf et al, 2010[82] 1 1 1 1 1 1 1 1 1 0 9 
33. Mann et al, 2016[32] 1 1 1 1 1 1 1 1 1 0 9 
34. Mauskopf et al, 2012[48] 1 1 1 1 1 1 1 1 1 0 9 
35. Mauskopf et al, 2005[89] 1 1 0 1 1 1 1 1 1 0 8 
36. Millham et al, 2020[69] 1 1 1 1 1 1 1 1 1 0 9 
37. Nakagawa et al, 2015[3] 1 1 0 1 1 1 1 1 1 1 
 
9 
38. Moreno et al, 2017[20] 1 1 1 1 1 1 1 1 0 1 9 
39. Ong et al, 2019[24] 1 1 1 1 1 1 1 1 1 1 10 
40. Ouellet et al, 2015[85] 1 1 1 1 1 1 1 1 0 0 8 
41. Owiti et al, 2014[57] 1 1 1 0 1 1 0 1 0 0 6 
42. Paltiel et al, 2017[64] 1 1 1 0 1 1 1 1 0 0 7 
43. Pinkerton et al, 1999[33] 0 1 0 1 1 1 1 0 1 0 6 
44. Reyes-Urueña et al, 2018[86] 1 1 1 1 1 1 1 0 0 0 7 
45. Rampaul et al, 2018[93] 1 1 0 1 1 1 1 1 1 0 8 
46. Schackman et al, 2006[8] 1 1 0 1 1 1 1 1 1 1 9 
47. Schackman et al, 2015[22] 1 1 1 1 1 1 1 1 1 1 10 
48. Sempa et al, 2012[16] 1 1 0 1 1 1 1 1 1 0 8 
49. Sloan et al, 2012[49] 1 1 1 1 1 1 1 1 1 1 10 
50. Yazdanpanah et al, 2002[71] 1 1 0 0 1 1 1 1 1 0 7 
51. Sweet et al, 2016[61] 1 1 1 1 1 1 1 1 1 0 9 
52. Uthman et al, 2018[15] 1 1 1 1 1 1 1 1 0 0 8 
53. VanDeusen et al, 2015[77] 1 1 1 1 1 1 0 1 0 0 7 
54. Walensky and Ross 
et al, 2013[76] 
1 1 1 1 0 1 1 1 0 0 7 
55. Walensky et al, 2013[55] 1 1 1 1 1 1 1 1 1 1 10 
56. Wolf et al, 2007[72] 1 1 1 1 1 1 1 1 1 0 9 
57. Leisegang et al, 2013[54] 1 1 1 1 1 1 1 1 1 0 9 
58 Liu et al, 2002[35] 1 1 1 1 1 1 1 1 1 1 10 
59. Johri et al, 2002[34] 1 1 1 1 1 1 1 1 1 0 9 
60. Kowalska et al, 2017[63] 1 1 1 1 1 1 0 1 1 0 8 




62. Pialoux et al, 2015[60] 1 1 1 1 1 1 1 1 1 0 9 
63. Restelli et al, 2017[21] 1 1 0 1 1 1 1 1 1 0 8 
64. Sax et al, 2010[75] 1 1 1 1 1 1 1 1 1 0 9 
65. Schackman et al, 2007[79] 0 1 1 1 1 1 1 1 1 0 8 
66. Simpson et al, 2013[18] 1 1 1 1 1 1 1 1 1 0 9 
67. Taychakhoonavudh et al, 
2016[62] 
0 1 1 1 1 1 0 1 0 0 6 
68. Tilden et al, 2010[46]* 
*Lifetime cost was taken 
from Chaudhary et al, 
2011[45] 
0 1 1 1 0 1 0 1 0 0 5 
69. Tremblay et al, 2018[87] 1 1 1 1 1 1 1 1 1 0 9 
70. Ward et al, 2018[94] 1 1 0 1 1 1 1 1 0 0 7 
71. Zheng et al, 2018[67] 1 1 1 1 1 1 1 1 1 0 9 
72. Moeremans et al, 2010[91] 1 1 0 1 1 1 1 1 0 0 7 
73. Moreno et al, 2010[42] 1 1 1 1 1 1 1 1 0 0 8 
74. Simpson et al, 2009[95] 1 1 1 1 1 1 1 1 1 1 10 
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